RESULTS: Forty-nine patients with a median of 4 prior lines of chemotherapy received at least 1 vaccination. Twenty-eight patients completed the 3 vaccination regimen. Six patients received 1 six-month boost after the regimen, and one patient received 7 six-month boosts. No serious adverse reactions or dose-limiting toxicities were observed. The vaccine was well tolerated with dose level 2 as the recommended phase II dose. The most common related toxicity in all patients was injection site reactions (24%). Two patients had a partial response (PR), 14 had stable disease (SD), and 19 had progressive disease (PD). CONCLUSIONS: The study vaccine is safe, exhibits anti-tumor activity and shows preliminary indication that peptide vaccination may avoid therapeutic resistance and offer a promising alternative to monoclonal antibody therapies.
- Received December 7, 2018.
- Revision received January 18, 2019.
- Accepted February 21, 2019
- Forums
- ASX - By Stock
- Ann: Clinical Cancer Research Journal publish B-Vaxx Phase 1 Data
RESULTS: Forty-nine patients with a median of 4 prior lines of...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.9¢ |
Change
0.002(5.41%) |
Mkt cap ! $386.7M |
Open | High | Low | Value | Volume |
3.6¢ | 4.0¢ | 3.5¢ | $1.163M | 31.27M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 2275218 | 3.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.9¢ | 196677 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 5665336 | 0.018 |
14 | 3997559 | 0.017 |
6 | 2974375 | 0.016 |
10 | 3219799 | 0.015 |
4 | 497500 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.019 | 400000 | 2 |
0.020 | 5410946 | 12 |
0.021 | 8494780 | 17 |
0.022 | 8757253 | 13 |
0.023 | 4826614 | 8 |
Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |